Document 2400
 DOCN  M94A2400
 TI    Viral hepatitis in the HIV-infected woman.
 DT    9412
 AU    Kloser P; Passanante M; Mayberry B; Gill C; Cowan J; UMDNJ.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):312 (abstract no. PC0176). Unique
       Identifier : AIDSLINE ICA10/94370175
 AB    OBJECTIVE: To compare the incidence and effect of viral hepatitis
       between ever intravenous (IVU) drug use and never intravenous drug use
       among HIV-infected women in NWAC (Newark Women's AIDS Clinic). METHOD: A
       random retrospective chart review of 146 HIV-infected women at
       comparable disease stages with and without IVU history. RESULTS: TABULAR
       DATA, SEE ABSTRACT VOLUME. CONCLUSION: HBV or HCV are present in close
       to 40% of NWAC patients and is a problem in our practice. HCV infection
       is equally likely in IVU and non-IVU while HBV alone or with HCV is more
       likely in IVU. A large percentage of those with HBV are surface antibody
       negative. Many women show evidence of liver disease via elevated
       transaminase levels. Implications include: HIV testing of those with
       evidence of HBV and/or HCV; HBV vaccine for those without positive
       antibody and appropriate changes in prescribing practice in HIV-infected
       women with liver disease.
 DE    Female  Hepatitis B/*COMPLICATIONS/DIAGNOSIS  Hepatitis
       C/*COMPLICATIONS/DIAGNOSIS  Human  HIV
       Infections/*COMPLICATIONS/DIAGNOSIS  Retrospective Studies  Substance
       Abuse, Intravenous/COMPLICATIONS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).